Successful Resolution of a Large Left Ventricular Thrombus with Rivaroxaban

Diana DeCampos, MD, João Lopes, MD, Carolina Saleiro, MD, Luís Puga, MD, José Pedro Sousa, MD, Ana Rita Morgado Gomes, MD, Rogério Teixeira, PhD, and Lino Gonçalves, PhD, Coimbra, Portugal

INTRODUCTION

Left ventricular (LV) thrombus is a complication commonly seen in systolic dysfunction, particularly after acute myocardial infarction (AMI). The main risk associated with LV thrombi is systemic embolization, namely stroke, which predominantly occurs within 1 year after AMI. Current guidelines recommend the use of vitamin K antagonists in patients with LV thrombus. At present, no robust data on the use of direct oral anticoagulants (DOACs) for the treatment of LV thrombi are available. We report a case of rivaroxaban-induced resolution of a large LV thrombus in a patient presenting with ST-segment elevation myocardial infarction (STEMI).

CASE PRESENTATION

A 61-year-old man with a history of dyslipidemia and hypertension presented to the emergency department 8 hours after an episode of intense chest pain. On arrival, his blood pressure was 140/95 mm Hg, heart rate 80 beats/min, and oxygen saturation 98%. Physical examination was remarkable only for inspiratory crackles on lung auscultation. Electrocardiography revealed a 3- to 4-mm ST-segment elevation from leads V1 to V4 with Q-wave formation and reciprocal ST-segment depression in the inferior leads. Primary angioplasty of the occluded left anterior descending coronary artery was performed with success. A subsequent transthoracic echocardiography demonstrated LV ejection function of 34% with an apical aneurysm and akinesis of the contiguous myocardial segments. An apical thrombus adherent to the LV wall was seen, measuring 22 × 28 mm (Figures 1 and 2, Video 1). In addition to dual-antiplatelet therapy (aspirin 100 mg/day, clopidogrel 75 mg/day), the patient started oral anticoagulation (rivaroxaban 20 mg/day after meals). Hospital recovery was uneventful. The patient was discharged with guideline-directed medical therapy and two follow-up appointments.

DISCUSSION

In this case report we present the complete resolution of a large LV thrombus 30 days after STEMI. Proper management of these thrombi is still controversial because there are limited data, especially on established left-sided intracardiac thrombi.

Contemporary data suggest that the incidence of LV thrombus may be as high as 15% in patients with STEMI and up to 25% in patients with anterior AMI. Those at high risk for apical LV thrombus are those with large or anterior AMI or severe apical hypokinesia and those receiving delayed reperfusion. Higher embolic potential is associated with protruding configuration and patterns of mobility of the LV thrombi. However, time-course variation in shape and mobility are not uncommon, and therefore the embolic risk is somewhat unpredictable.

Current European Society of Cardiology guidelines recommend the use of anticoagulation for up to 6 months, guided by repeated imaging (class IIa, level of evidence C). In ROCKET-AF trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in nonvalvular atrial fibrillation. Among patients excluded were those with LV thrombus. Recent prospective and retrospective data have shown that two thirds of left atrial and left atrial appendage thrombi resolve or are reduced in size after 6 weeks of rivaroxaban treatment. This was the first prospective study to show that DOACs, particularly rivaroxaban, may be a potential treatment option for left atrial and left atrial appendage thrombi. In an updated systematic review, most patients with LV thrombi were treated with rivaroxaban, with a rate of resolution of 81% within a median time of 40 days.

The optimal duration of anticoagulation therapy for LV thrombi is not clearly known. Some authors report that if after 3 months of...
therapy there is complete resolution of the thrombi, discontinuation of the DOAC earlier than 6 months can be considered, especially if there is recovery of apical wall motion. 

We acknowledge that the use of DOACs is not approved for the treatment of LV thrombi. A DOAC was chosen because of patient preference. There are two randomized controlled trials comparing a DOAC with a vitamin K antagonist in the resolution of LV thrombus after STEMI now recruiting patients (ClinicalTrials.gov identifiers NCT03232398 and NCT02982590).  

Figure 1 Transthoracic echocardiography, apical four- and two-chamber views with three-dimensional reconstruction: apical mural thrombus.

Figure 2 Transthoracic echocardiography, apical four-chamber view, zoomed: apical mural thrombus measuring 22 × 28 mm.
and on optimal dosing and timing when or if combined with dual- or single-antiplatelet therapy.

CONCLUSION

This case demonstrates a rapid and successful resolution of a large LV thrombus on DOAC therapy, specifically rivaroxaban. If enough clinical data support the relative efficacy and safety of DOACs in thrombus resolution, they might be more attractive than warfarin in the management of LV thrombi in systolic dysfunction. This may improve patient compliance and reduce length of stay.

SUPPLEMENTARY DATA

Supplementary data related to this article can be found at https://doi.org/10.1016/j.case.2020.04.006.

REFERENCES

1. Udell JA, Wang JT, Gladstone DJ, Tu JV. Anticoagulation after anterior myocardial infarction and the risk of stroke. PLoS One 2010;5:e12150.

2. McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi JL Jr, Bhatt DL, McEvoy JW. Left ventricular thrombus after acute myocardial infarction: screening, prevention, and treatment. JAMA Cardiol 2018;3:642-9.

3. Domenicucci S, Bellotti P, Chiarella F, Lupi G, Vecchio C. Spontaneous morphologic changes in left ventricular thromb: a prospective two-dimensional echocardiographic study. Circulation 1987;75:737-43.

4. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-77.

5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-91.

6. Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (XTRA) and a retrospective observational registry providing baseline data (CLOFT-AF). Am Heart J 2016;178:126-34.

7. Kajy M, Shokr M, Ramappa P. Use of direct oral anticoagulants in the treatment of left ventricular thrombus: systematic review of current literature. Am J Ther 2019. https://doi.org/10.1097/MJT.0000000000000937 [Epub ahead of print].

8. Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR
2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation Appropriate Use Criteria task force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol 2011;57:1126-66.

9. Apixaban versus warfarin in patients with left ventricular (LV) thrombus. Available at: https://clinicaltrials.gov/ct2/show/study/NCT03232398. Accessed May 5, 2020.

10. Apixaban versus warfarin in patients with left ventricular thrombus. Available at: https://clinicaltrials.gov/ct2/show/NCT02982590. Accessed May 5, 2020.